Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph early_phase_1
3
75%
Ph phase_1
1
25%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Early Phase 1First-in-human
3(75.0%)
Phase 1Safety & dosage
1(25.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Other(4)

Detailed Status

unknown4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
N/A
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 13 (75.0%)
Phase 11 (25.0%)

Trials by Status

unknown4100%

Recent Activity

0 active trials
Showing 4 of 4
unknownphase_1

Phase I/II Study of αPD1-MSLN-CAR T Cells in MSLN-positive Advanced Solid Tumors

NCT05944185
unknownearly_phase_1

αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors

NCT05373147
unknownearly_phase_1

αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors

NCT04503980
unknownearly_phase_1

αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors

NCT04489862

Clinical Trials (4)

Showing 4 of 4 trials
NCT05944185Phase 1

Phase I/II Study of αPD1-MSLN-CAR T Cells in MSLN-positive Advanced Solid Tumors

Unknown
NCT05373147Early Phase 1

αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors

Unknown
NCT04503980Early Phase 1

αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors

Unknown
NCT04489862Early Phase 1

αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4